NYSE:BDX

Becton Dickinson (BDX)

151.16
+1.60 (1.07%)
as of Jun 5, 2026, 8:00:00 pm Market Open.
131 watching
0
Investor Insights
star iconJun 7, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Becton Dickinson (BDX) has undergone significant structural changes, having recently spun off its life sciences business and merged it with Waters Corporation, thereby positioning itself as a pure-play medical technology company. This transformation aims to focus on higher-growth and higher-margin areas within the medical sector. Despite management's previous projections of $15 EPS, the new guidance suggests a more conservative estimate of $12.50 for 2026, while expectations for operating margins have risen from 21% to 25%. The stock is currently considered attractively priced at 14x earnings, but there are inherent risks associated with the ongoing changes. Furthermore, analysts have set a price target of $200.00, indicating a cautiously optimistic outlook. However, concerns remain regarding the macroeconomic environment, particularly given BDX's strong ties to hospital systems, which has caused some experts to adopt a wait-and-see approach before re-evaluating their investment stance.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
SYK
HOLD
Has been around for 100 years. Valuation is 15x earnings for 2021. Stock jumped today. Big free cash flow company. Made an acquisition of Bard, another free cash flow giant, so they're paying down debt quickly. So they'll have cash to make acquisitions or grow dividend. In comparing retail to medical devices, he'd always pick the medical device company.
TOP PICK
The oldest manufacturer of syringes and other medical devices. There is good growth in emerging countries. They will pay down debt and have attractive dividend growth. (Analysts’ price target is $263.10)
HOLD
Has owned for a while. One of the more defensive companies you can own. Medical things you can only use once. Sells a suite of products and software to hospitals. Lots of EM opportunities. Still has to pay down debt from an acquisition, but but in 12-18 months should be ready for another. Good place to be with aging demographics, especially in US.
WATCH
Merely an okay last quarter with cost increases and more debt after an acquisition. Resin cost inputs are worth watching. Trades at 18x earnings. Watching this closely. Neutral.
PAST TOP PICK
(A Top Pick Nov 07/17, Up 10%) Their big thing is drug delivery equipment. They have a lot of things going for them. They had a messy quarter. It is why he prefers to use ETFs for this. It was not a small pull back for them. The acquisition gives them some synergy on costs.
TOP PICK

They make medical devides (syringes, blood test equipment). After last year's acqusition, there are two cash-flow companies here which excites him. He's owned this for a decade. 1.3% dividend. 10% dividend and price growth. (Analysts’ price target is $270.50)

PAST TOP PICK

(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.

PAST TOP PICK

(A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it.

TOP PICK

A great up trending stock chart. It is consolidating at the moment with lots of time to grow. Yield 1.3%. (Analysts’ price target is $251.11)

BUY

U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics.

PAST TOP PICK

(A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years.

PARTIAL BUY

He sees this as a good company, but not in his top 25. Healthcare technology has been very profitable and medical consumables is a niche area. There is good opportunity to grow through value add like prefilled syringes. He sees them as a high quality, low cost provider.

BUY

They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space.

BUY

It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.

COMMENT

Manufactures syringes and other medical devices. Just completed a big merger. The merger of 2 strong free cash flow growing companies has made them a powerhouse, and the stock has taken off after the announcement of the acquisition. Expectation is 10% free cash flow growth, and as a result, 10% dividend growth over time.

Showing 46 to 60 of 91 entries